97th DOG Annual Meeting 1999
MYCOPHENOLATE MOFETIL (CELLSEPT®) AS IMMUNOSUPPRESSANT IN THERAPY OF UVEITIS
M. Zierhut1, B. Aboalchamat2, H. Landenberger1, K. Engelmann2
Severe forms of uveitis often only can be managed sufficiently with systemic immunosuppression. All available drugs are known for their relative high rate of side effects. Mycophenolate mofetil (MMF), an immunosuppressant successfully used in management after organ transplantation and many autoimmune deseases has shown remarkable less side effects. Goal of this presented study is to analyse the effect and the side effects of MMF used in various forms of uveitis as monotherapy.
Method: Ten patients with anterior uveitis (n=3), intermediate uveitis (n=2), panuveitis (n=4) and retinal vasculitis (n=1) were treated in a prospective study with 2x1g MMF daily. Previous immunosuppression was stopped because of side effects or Ineffectivity in all the patients.
Results: The follow-up time ranged between 1 to 12 months. Under therapy with MMF we found no recurrence in 8 patients. In one female patient depression of inflammation activity only was achieved with methotrexat. Another patient needed additive steroid therapy to keep both eyes in a quiet state. Mentioned side effects were diarrhoia in one patient ( - leading to stop of therapy ) and in another case nausea, vomitus and alopecia.
Conclusion: MMF as a monotherapeutical immunosuppressant had stopped inflammation in 8 of 10 patients with uveitis, previously not controlled by other immunosuppressants. The side effects were tolerable in comparison with other immunosuppressants. More patients and longer follow-up times are required to judge longterm therapeutical success.
1 Universitäts-Augenklinik, Schleichstr. 12, D-72072 Tübingen
2 Universitäts-Augenklinik, Martinistr. 52, D-20246 Hamburg